相关实验视频

Updated: Jun 9, 2026

A Protocol for Comprehensive Assessment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis ALS

A Protocol for Comprehensive Assessment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis ALS

Published on: February 21, 2011

ALS的自然史:来自多中心临床队列的基线特征

Alex Berger¹, Matteo Locatelli¹, Ximena Arcila-Londono²

¹Neurological Clinical Research Institute, Massachusetts General Hospital, Boston, MA, United States.

Amyotrophic lateral sclerosis & frontotemporal degeneration

|July 18, 2023

概括

美国ALS自然历史联盟 (ALS NHC) 从1925名患者中收集了全面的数据,显示出比临床试验数据更大的异质性. 这一数据集增强了对肌缩性侧面硬化症 (ALS) 的理解,以改善研究和治疗.

科学领域:

神经学神经学
临床研究临床研究
数据科学数据科学数据科学

背景情况:

肌缩侧面硬化症 (ALS) 研究迫切需要改进治疗方法和更充分地了解疾病的自然史.
由于限制性资格标准,目前的临床试验数据可能不代表整个ALS患者群体.
现有的生物标志物和队列研究虽然更具包容性,但如果参与负担很高,可能仍然无法捕捉ALS表型的全部谱.

研究的目的:

建立一个全面的数据集的肌缩性侧面硬化症 (ALS) 的人口,反映现实世界的患者多样性.
为了解决当前ALS研究数据的局限性,这些数据往往缺乏对整个患者群体的概括性.
通过从广泛的ALS患者中收集广泛的数据,促进对ALS异质性的全面理解.

主要方法:

成立了ALS自然历史联盟 (ALS NHC),涉及9个ALS诊所.
该联盟旨在实现最大限度的患者参与,大约95%的接触患者同意加入.
在获得同意后,从每个参与者的电子健康记录中抽取了最小的数据集,从而最大限度地降低了患者的负担.

主要成果:

截至2022年12月9日,来自1925名ALS患者的数据已提交到ALS NHC.
与ALS临床试验数据库 (PRO-ACT) 的匿名数据相比,ALS NHC的参与者表现出更大的异质性.
该ALS NHC队列包括患病年龄较高的患者,并且El Escorial类别的分布比PRO-ACT数据库更广泛.

结论:

与ALS临床试验相比,ALS NHC参与者在诊断和人口统计数据中表现出更高的多样性.
这种基于临床的纵向数据集有助于更好地了解ALS自然史.
这些数据可以为临床试验设计,健康经济学研究,临床过程预测和ALS治疗和护理实践的现实世界证据文档提供信息.

关键词:

自然历史自然历史的历史.流行病学流行病学模型模型模型模型预后预测预测的预测.

更多相关视频

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS

Published on: March 17, 2012

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis

Published on: March 4, 2014

相关概念视频

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...

Multiple Sclerosis l: Introduction

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

Alzheimer Disease l: Introduction

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...

Alzheimer Disease ll: Pathophysiology

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...

Huntington Disease l: Introduction

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...